Stockscreener 앱 받기
0.9934
5.39%
-0.0566
전일 마감가:
$1.05
열려 있는:
$1.06
하루 거래량:
641.42K
Relative Volume:
1.01
시가총액:
$42.40M
수익:
순이익/손실:
$-40.92M
주가수익비율:
-0.5787
EPS:
-1.7167
순현금흐름:
$-26.53M
1주 성능:
-17.90%
1개월 성능:
-4.48%
6개월 성능:
-44.19%
1년 성능:
-51.06%
1일 변동 폭
$0.987
$1.08
1주일 범위
$0.987
$1.21
52주 변동 폭
$0.987
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
0.9934 | 42.40M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-08 | 개시 | Roth Capital | Buy |
| 2025-02-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Uses AI Platform to Accelerate Buntanetap FDA Filing - MyChesCo
Annovis Bio stock reports 862 Phase 3 enrollments - ad-hoc-news.de
Annovis Bio, Inc. Announces Partnership With Weave Bio In Preparation Of NDA For Buntanetap In Alzheimer?s Disease - marketscreener.com
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Australia
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Canada
Annovis Bio partners with Weave Bio for NDA preparation - Investing.com
Annovis Announces Partnership with Weave Bio, AI Regulatory - GlobeNewswire
Annovis Bio announces special shareholder meeting - Bitget
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - ad-hoc-news.de
Annovis Bio Stock Price Forecast. Should You Buy ANVS? - StockInvest.us
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - TradingView
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Momentum Breakout Ideas - vinanet.vn
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Andrews Pitchfork - dars.gov.et
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesBearish Pattern Stocks - vinanet.vn
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesMFI Divergence - dars.gov.et
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineProfit Announcement - vinanet.vn
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Annovis to Host Corporate Update Webinar on September 2, 2026 - Yahoo Finance
Annovis says Alzheimer’s trial is fully enrolled, with data expected in 2027 - Stock Titan
Annovis (ANVS) Results Breakdown: Profit Per Share Falls Below Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - theglobeandmail.com
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Trend Continuation Trade - dars.gov.et
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Caledonian Record
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - GlobeNewswire
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Annovis Bio Inc 주식 (ANVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director |
Apr 02 '26 |
Buy |
2.10 |
713,800 |
1,498,980 |
3,288,539 |
| White Mark K. | Director |
Apr 02 '26 |
Proposed Sale |
2.08 |
7,142 |
14,848 |
0 |
| Hoffman Michael B | Director |
Dec 08 '25 |
Buy |
4.31 |
45,000 |
193,794 |
2,574,739 |
| Hoffman Michael B | Director |
Nov 24 '25 |
Buy |
4.08 |
39,200 |
159,886 |
2,519,739 |
| Hoffman Michael B | Director |
Nov 21 '25 |
Buy |
3.50 |
20,000 |
69,900 |
2,490,539 |
| Hoffman Michael B | Director |
Nov 14 '25 |
Buy |
2.11 |
15,000 |
31,650 |
2,470,539 |
| Maccecchini Maria-Luisa | President & CEO |
Oct 28 '25 |
Buy |
2.05 |
97,561 |
200,000 |
1,212,020 |
| Hoffman Michael B | Director |
Oct 28 '25 |
Buy |
2.05 |
975,610 |
2,000,000 |
2,455,539 |
4.22%
자본화:
|
볼륨(24시간):